JP2024037932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024037932A5 JP2024037932A5 JP2023212722A JP2023212722A JP2024037932A5 JP 2024037932 A5 JP2024037932 A5 JP 2024037932A5 JP 2023212722 A JP2023212722 A JP 2023212722A JP 2023212722 A JP2023212722 A JP 2023212722A JP 2024037932 A5 JP2024037932 A5 JP 2024037932A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- antibody
- human
- cdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052933P | 2020-07-16 | 2020-07-16 | |
| US63/052,933 | 2020-07-16 | ||
| PCT/US2021/070898 WO2022016198A1 (en) | 2020-07-16 | 2021-07-16 | Anti-αlpha-4-βeta-7 antibodies |
| JP2023502654A JP7408008B2 (ja) | 2020-07-16 | 2021-07-16 | 抗アルファ－４－ベータ－７抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502654A Division JP7408008B2 (ja) | 2020-07-16 | 2021-07-16 | 抗アルファ－４－ベータ－７抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024037932A JP2024037932A (ja) | 2024-03-19 |
| JP2024037932A5 true JP2024037932A5 (enExample) | 2024-07-19 |
| JP7765447B2 JP7765447B2 (ja) | 2025-11-06 |
Family
ID=77338969
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502654A Active JP7408008B2 (ja) | 2020-07-16 | 2021-07-16 | 抗アルファ－４－ベータ－７抗体 |
| JP2023212722A Active JP7765447B2 (ja) | 2020-07-16 | 2023-12-18 | 抗アルファ－４－ベータ－７抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502654A Active JP7408008B2 (ja) | 2020-07-16 | 2021-07-16 | 抗アルファ－４－ベータ－７抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11639390B2 (enExample) |
| EP (1) | EP4182349A1 (enExample) |
| JP (2) | JP7408008B2 (enExample) |
| KR (1) | KR20230038728A (enExample) |
| CN (1) | CN115867352A (enExample) |
| AR (1) | AR122983A1 (enExample) |
| AU (1) | AU2021307468A1 (enExample) |
| CA (1) | CA3188739A1 (enExample) |
| CO (1) | CO2023001066A2 (enExample) |
| IL (1) | IL299767A (enExample) |
| MX (1) | MX2023000732A (enExample) |
| TW (1) | TWI889871B (enExample) |
| UY (1) | UY39327A (enExample) |
| WO (1) | WO2022016198A1 (enExample) |
| ZA (1) | ZA202300222B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| WO2025038861A1 (en) * | 2023-08-15 | 2025-02-20 | Abbvie Inc. | Methods of treating human immunodeficiency virus (hiv) disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1135498B1 (en) | 1998-11-18 | 2008-01-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| AP2015008338A0 (en) * | 2012-09-26 | 2015-04-30 | Kflp Biotech Llc | Compounds for the treatment and prevention of retroviral infections |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
-
2021
- 2021-07-15 UY UY0001039327A patent/UY39327A/es unknown
- 2021-07-15 AR ARP210101993A patent/AR122983A1/es unknown
- 2021-07-16 MX MX2023000732A patent/MX2023000732A/es unknown
- 2021-07-16 US US17/378,565 patent/US11639390B2/en active Active
- 2021-07-16 WO PCT/US2021/070898 patent/WO2022016198A1/en not_active Ceased
- 2021-07-16 EP EP21755330.4A patent/EP4182349A1/en active Pending
- 2021-07-16 JP JP2023502654A patent/JP7408008B2/ja active Active
- 2021-07-16 AU AU2021307468A patent/AU2021307468A1/en active Pending
- 2021-07-16 CN CN202180049613.2A patent/CN115867352A/zh active Pending
- 2021-07-16 TW TW110126301A patent/TWI889871B/zh active
- 2021-07-16 CA CA3188739A patent/CA3188739A1/en active Pending
- 2021-07-16 KR KR1020237004136A patent/KR20230038728A/ko active Pending
- 2021-07-16 IL IL299767A patent/IL299767A/en unknown
-
2023
- 2023-01-04 ZA ZA2023/00222A patent/ZA202300222B/en unknown
- 2023-01-31 CO CONC2023/0001066A patent/CO2023001066A2/es unknown
- 2023-12-18 JP JP2023212722A patent/JP7765447B2/ja active Active
-
2025
- 2025-03-19 US US19/083,890 patent/US20260062488A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037932A5 (enExample) | ||
| WO2022022445A1 (zh) | 一种特异性结合冠状病毒的抗体或其抗原结合片段 | |
| Walker et al. | Passive immunotherapy of viral infections:'super-antibodies' enter the fray | |
| JP6811723B2 (ja) | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 | |
| AU2016347058B2 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection | |
| JP2020184996A5 (enExample) | ||
| Chen et al. | Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis | |
| TWI789711B (zh) | 新型冠狀病毒的人源單克隆抗體及其應用 | |
| TWI889729B (zh) | 針對ｈｉｖ之廣泛中和抗體 | |
| JP2016516400A (ja) | Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体 | |
| CN114106191A (zh) | 一种中和冠状病毒的双特异性抗体 | |
| EP3110844B1 (en) | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region | |
| CN109929033B (zh) | 一种特异性结合四种血清型登革病毒的人源抗体 | |
| JP2012513457A (ja) | Ｈｃｖ感染の治療的処置および予防のための医薬としての抗ｈｃｖモノクローナル抗体 | |
| CN114656556B (zh) | 一种抗新型冠状病毒的全人源单克隆抗体及其应用 | |
| Zhu et al. | Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses | |
| Lu et al. | Potent neutralization ability of a human monoclonal antibody against serotype 1 dengue virus | |
| de Souza et al. | Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens | |
| Zhang et al. | Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies | |
| CN103755805B (zh) | HIV-1 Env特异性的全人单克隆抗体 | |
| CN112661852A (zh) | 针对乙肝病毒的双特异性抗体及其应用 | |
| CN117402237A (zh) | 一种抗新型冠状病毒的双特异性抗体及其应用 | |
| WO2024022438A1 (zh) | 一种抗rbd抗体及其用途 | |
| CN114751988A (zh) | 中和冠状病毒的多特异性抗体 | |
| CN114751986A (zh) | 中和新冠病毒的多特异性抗体 |